WESTMINSTER, Colo., June 25 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that it was selected to
join the broad-market Russell 3000(R) Index. This inclusion was effective
at the close of trading on June 22, 2007, when the Russell Investment Group
reconstituted its set of U.S. and global equity indexes. Annual
reconstitution of Russell's U.S. indexes captures the 3,000 largest U.S.
stocks as of the end of May, ranking them by total market capitalization.
The largest 1,000 companies in this ranking comprise the Russell 1000(R)
Index and the next largest 2,000 companies become the Russell 2000(R)
Index. The Russell 3000(R) Index serves as the U.S. component of the
Russell Global(R) Index.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both passive
and active investment strategies. According to the Russell Investment
Group, an industry-leading $4 trillion in assets currently are benchmarked
to Russell indexes.
About Allos
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in a
pivotal Phase 2 trial in patients with relapsed or refractory peripheral
T-cell lymphoma. The Company is also investigating PDX in patients with non
small cell lung cancer and a range of other lymphoma sub-types. The
Company's other product candidate is RH1, a targeted chemotherapeutic agent
for which the Company expects to initiate a Phase 1 study in patients with
advanced solid tumors in the second half of 2007. For additional
information, please visit the Company's website at http://www.allos.com.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Derek Cole, Vice President, Investor
Relations, +1-720-540-5367, dcole@allos.com; or Jennifer Neiman,
Senior Manager, Corporate Communications, +1-720-540-5227,
jneiman@allos.com, both of Allos Therapeutics, Inc.
|
